1212results about "Ester active ingredients" patented technology

The invention relates to the technical field of probiotics, in particular to a combined fungicide for improving Alzheimer's disease and application of the combined fungicide. The combined microbial agent is prepared from lactobacillus gasseri LFLG-245 and inactivated Ackermania muciniphila AKKLF (Ackermania muciniphila AKKLF); the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the lactobacillus gasseri LFLG-245 is CGMCC (China General Microbiological Culture Collection Center) No.33952. The lactobacillus gasseri LFLG-245 has the advantages that the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center; the Akkermansia muciniphila AKKLF is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the Akkermansia muciniphila AKKLF is CGMCC (China General Microbiological Culture Collection Center) No.33955. The Akkermansia muciniphila AKKLF disclosed by the invention has the advantages that the Akkermansia muciniphila AKKLF can be applied to the field of biological The combined microbial agent provided by the invention can improve the Alzheimer's disease.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I):wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. An insulin secretion-promoting action of the pentadecanoic acid triglyceride at the time of elevated blood glucose level is discovered, and pharmaceuticals and health foods for improving blood glucose level and diabetes are provided using this triglyceride.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention relates to the technical field of liposomes, in particular to a lutein ester-fumaric acid composite liposome with high bioavailability as well as a preparation method and application of the lutein ester-fumaric acid composite liposome. The preparation method of the lutein ester-fumaric acid composite liposome comprises the following steps: mixing lutein ester with oil to obtain a phase A; adding phospholipid, cholesterol and vitamin E into the phase A, and then carrying out ultrasonic dispersion treatment to obtain a phase B; fumaric acid and water are added into the phase B, and then high-pressure homogenization treatment, high-pressure microjet treatment and freeze-drying treatment are sequentially performed to obtain the lutein ester-fumaric acid composite liposome. The lutein ester-fumaric acid composite liposome with high bioavailability has the advantages of small average particle size, high Zeta potential, high encapsulation efficiency, high bioavailability, high solubility and excellent stability, and has potential application prospects in preparation of foods, medicines or health care products with eye protection functions.

Provided is a collagen production promoter comprising, as an active ingredient, a triglyceride represented by the following formula (I), wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. The triglyceride comprising the pentadecanoic acid promotes the production of skin fibroblasts and collagen, and can be used as a topical skin care composition and a beauty food or beverage for improving the condition of skin.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention provides application of a copper death inducer in preparation of a medicine for treating osimertinib-resistant non-small cell lung cancer, and belongs to the technical field of treatment of non-small cell lung cancer. According to the invention, through high-throughput drug screening, the copper death inducer copper diethyl dithiocarbamate (CuET) and osimertinib are combined for use, so that a remarkable synergistic anti-cancer effect is achieved; furthermore, through detection of a wild type and osimertinib drug-resistant cell line model, an osimertinib sensitive and drug-resistant patient-derived organoid and a mouse xenotransplantation model, it is found that the anti-tumor effect of osimertinib can be remarkably enhanced through copper death induction, and osimertinib drug resistance is overcome. According to the technical scheme provided by the invention, osimertinib drug-resistant non-small cell lung cancer cells can be effectively killed, the curative effect of osimertinib in sensitive and drug-resistant models is remarkably enhanced, and an application scene is provided for copper death in tumor treatment.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Disclosed is a process for the synthesis of mono- and bis-nitrosylated propanediols, as well as compositions and pharmaceutical formulations that includes the compounds. The process proceeds by reacting a corresponding propanediol that is not nitrosylated with a source of nitrite, optionally in the presence of a suitable acid. When the source of nitrite is an organic nitrite, reacting step is performed in a suitable organic solvent, and when the source of nitrite is an inorganic nitrite, the reacting step is performed in a bi-phasic solvent mixture comprising an aqueous phase and a non-aqueous phase. Also disclosed are methods of treating a condition wherein administration of nitric oxide (NO) has a beneficial effect by administering said compounds, compositions or formulations.

The present disclosure provides pharmaceutical and nutritional compositions and methods for treating mitochondrial disorders. The present invention relates to a pharmaceutical or nutritional composition comprising a stabilized sulforaphene (e.g., a sulforaphene-cyclodextrin complex) that improves the efficacy, biological activity, and stability of the isolated sulforaphene. The disclosure also includes the use of the stabilized sulforaphene as an effective therapeutic agent for the treatment of mitochondrial disorders, such as mitochondrial myopathy.

Provided is a composition for visual field defect disorders, glaucoma, light-induced ocular tissue damage and related disorders, which can be used as a food or drug for long-term administration, prevention, symptom relief and improvement. A composition comprising a triglyceride represented by the formula (I):(wherein R1, R2, and R3 are each a saturated fatty acid residue, and at least one of them is a pentadecanoic acid residue) as an active ingredient.

Novel compositions are described, each comprising at least one active constituent that has a 12-carbon atom backbone as a 12-carbon chain base structure having at least a sub-terminal nitrogen and no terminal amino group. One of the active constituents is Boc-12-Ado-OH (BOA) and / or N,N-dimethyldodecylamine N-oxide (LO). Novel particle or liposomal compositions comprising at least BOA and / or LO may be prepared with an emulsifier and / or lipid and optionally a biopolymer, and may be formulated into pharmaceutically acceptable formulations and / or medicaments with or without one or more pharmaceutically acceptable carriers or excipients for utilization as an antimicrobial against one or more microbial pathogens. The novel antimicrobial compositions have broad-spectrum growth inhibitory or other destructive activity against microbial pathogens, biofilms produced by one or more pathogens, and biofilm infections.

To provide antisense oligonucleotide sequences and methods of using the same for treating neurological diseases.SOLUTION: Provided is an oligonucleotide comprising linked nucleosides having a sequence of at least 19 contiguous nucleobases, wherein the sequence of nucleobases comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary to an equal length portion of nucleobases contained at a specified position of a specified sequence.SELECTED DRAWING: Figure 1A

A GRK2 protein inhibitor compound of Formula I wherein X is an atom selected from carbon and nitrogen, and R1 is selected from the groups methyl carboxylate and 1,3,4-oxadiazol-2-yl and wherein the compound is selected from methyl 4-(naphthalene-2-amido)benzoate and N-[4-(1,3,4-oxadiazol-2-yl)phenyl]quinoline-3-carboxamide. Also disclosed are pharmaceutical compositions comprising at least a compound of Formula I.

The present application relates to a pharmaceutical composition comprising an NRF2 agonist and borneol, both of which synergize in a specific molar ratio range, enhance the overall anti-inflammatory and antioxidant biological activity of the drug, improve the oral bioavailability and target tissue distribution of the drug, inhibit the off-target side effects of the NRF2 agonist, and significantly improve the effectiveness and safety of the drug.

The present invention discloses compositions and methods comprising enriched bisdemethoxycurcumin (BDMC) present at 20% by weight or greater for use in inhibiting receptor for advanced glycation end products (RAGE) expression in a subject with a chronic inflammatory condition. The composition further comprises beta-amyrin palmitate (BAP). The present invention also discloses the use of the composition in managing a chronic inflammatory condition in a subject.

The invention discloses application of polyol nitrate in frostbite resistance, and belongs to the technical field of skin protection articles. The polyol nitrate is used as an active component of the ointment, and by slowly releasing nitric oxide and activating vascular endothelial nitric oxide synthase, spasm capillaries in the early stage of frostbite are effectively relaxed, platelet aggregation and thrombosis are inhibited, so that the pathological cascade reaction of frostbite is blocked, and the prevention and treatment effects on frostbite are remarkably improved. Compared with the prior art, the polyol nitrate and the ointment are scientific and reasonable in preparation method and safe and convenient to use, and a brand-new and effective solution is provided for prevention and treatment of skin frostbite in a cold environment.

In certain embodiments, Formula I: 【Chemical 1】 Compounds of JPEG2025520456000046.jpg5339 or pharmaceutically acceptable salts or solvates thereof, compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and their use in the treatment of certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation) etc. are provided herein.

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and / or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.

Described herein are methods for administering myosin inhibitors to patients and associated methods for mitigating risk, including controlling distribution. The methods disclosed herein provide for the safe administration of mavacamten and other myosin inhibitors, mitigating the risk of heart failure due to systolic dysfunction.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The invention discloses a micropterus salmoides intestinal function feed additive based on composite synergy and application thereof, and belongs to the technical field of feed additives. The feed additive for improving the intestinal function of the largemouth bass comprises the following raw materials: clostridium butyricum, tributyrin, aspergillus niger and a plant source carrier. The invention provides a compound feed additive capable of remarkably improving the growth performance of the largemouth bass, improving the digestive enzyme activity of the intestinal tract and optimizing the intestinal barrier, and the compound feed additive can remarkably improve the weight gain rate and the specific growth rate of the largemouth bass, remarkably improve the digestive enzyme activity of the intestinal tract of the largemouth bass and maintain the integrity of the tissue structure of the intestinal tract. Compared with a single additive, the compound additive shows a better synergistic gain effect in the aspect of comprehensive effects, has important value for promoting research, development and practical application of novel feed additives of micropterus salmoides, has good popularization and application prospects, and is expected to bring remarkable economic benefits to the breeding industry.

The invention relates to a pharmaceutical composition, which is prepared from adapalene, benzoyl peroxide, a traditional Chinese medicine extract, an acrylamide and acryloyl dimethyl sodium taurate copolymer, a mixture of isohexadecane and polysorbate 80, docusate sodium, EDTA (Ethylene Diamine Tetraacetic Acid) disodium, glycerol, poloxamer 124, propylene glycol and water, the traditional Chinese medicine extract comprises moutan bark, salvia miltiorrhiza, radix rehmanniae recen, radix sophorae flavescentis, coptis chinensis, rheum officinale, scutellaria baicalensis, menthol and borneol. According to the pharmaceutical composition disclosed by the invention, the synergistic antibacterial and anti-keratosis curative effects of adapalene and benzoyl peroxide can be maintained, and meanwhile, the occurrence rate of local skin dryness, erythema, desquamation, burning heat sensation and contact dermatitis can be remarkably reduced.

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

Induced Pluripotent Stem Cell (iPSC) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD. Due to their early onset and nonfamilial origin, differentiated nervous tissue from these patients offer a key opportunity to discover neuron subtype specific pathological mechanisms and importantly interrogate the contribution of their genetic background in susceptibility to PD.

Methods improve cognitive functioning, for example, at least one of episodic memory, executive function, or language skills; supporting memory and / or recall; providing energy and / or ketones to the brain; and / or preventing and / or treating mild cognitive impairment (MCI) in an individual. A composition comprising medium chain triglycerides (MCTs) can be administered to the individual in a daily dosage providing from about 15 g to about 45 g MCTs. The MCTs can include from about 51 wt % to about 90 wt % of octanoic acid. The daily dose can be provided in at least two servings, for example, 2 or 3 servings. Each serving can provide about 15 g MCTs and can include octanoic acid and decanoic acid in a weight ratio of, for example, about 60:about 40. The individual can be 65 years or older and / or have mild cognitive impairment (MCI).